186 related articles for article (PubMed ID: 29509243)
21. Human endometrial cytodifferentiation by histone deacetylase inhibitors.
Uchida H; Maruyama T; Nagashima T; Ono M; Masuda H; Arase T; Sugiura I; Onouchi M; Kajitani T; Asada H; Yoshimura Y
Hum Cell; 2006 Feb; 19(1):38-42. PubMed ID: 16643606
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
23. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
24. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
26. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Matsuda K; Kusumoto M; Narahara H
Oncology; 2006; 70(2):97-105. PubMed ID: 16601366
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors: a review on class-I specific inhibition.
Behera J; Jayaprakash V; Sinha BN
Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
[TBL] [Abstract][Full Text] [Related]
28. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
29. Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid.
Johnson J; Hunter R; McElveen R; Qian XH; Baliga BS; Pace BS
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):229-38. PubMed ID: 16171558
[TBL] [Abstract][Full Text] [Related]
30. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
32. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Jiang S; Dowdy SC; Meng XW; Wang Z; Jones MB; Podratz KC; Jiang SW
Gynecol Oncol; 2007 May; 105(2):493-500. PubMed ID: 17303224
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Ahn MY; Chung HY; Choi WS; Lee BM; Yoon S; Kim HS
Int J Oncol; 2010 Jan; 36(1):125-31. PubMed ID: 19956841
[TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
36. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
37. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice.
Banno K; Kisu I; Yanokura M; Masuda K; Ueki A; Kobayashi Y; Susumu N; Aoki D
Epigenomics; 2012 Apr; 4(2):147-62. PubMed ID: 22449187
[TBL] [Abstract][Full Text] [Related]
38. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Lee EJ; Lee BB; Kim SJ; Park YD; Park J; Kim DH
Int J Oncol; 2008 Oct; 33(4):767-76. PubMed ID: 18813790
[TBL] [Abstract][Full Text] [Related]
40. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
